Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up News

Executive Summary

Noteworthy news from medtech start-ups. This month we profile Epicardial Technologies Inc., which is developing technology for percutaneous epicardial ablation of heart arrhythmias, Svelte Medical's technology for enhancing stent deliverability, Bioring's biodegradable annuloplasty ring and Advanced BioSensor's second-generation glucose monitoring device.

You may also be interested in...



The Future of Drug-Eluting Stents Part II: Biodegradable Platforms

The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. However, many researchers in this field believe the future of stenting will be defined by completely biodegradable stents that do their job of propping open the vessel until healing occurs, and gradually degrade over a period of months or years, leaving nothing permanently behind in the vessel.

The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs

Growth by innovation is almost considered a birthright in interventional cardiology, and based on presentations at this year's Transcatheter Cardiovascular Therapeutics meeting, held this September in San Francisco, it seems clear that innovation still reigns supreme in this specialty. However, as in other medical device markets, ongoing economic and regulatory pressures are taking their toll, particularly in the drug-eluting stent market, as the field adjusts to a new era of cost control and economic uncertainty.

Vascular Access Closure Ten Years Later: Why Start-Ups Can't Seal the Deal

Despite the best intentions and brightest innovation, start-ups haven't been able to tap into the huge potential presented by the vascular closure market. Ten years after the first generation devices made it to market, the original two leaders still dominate despite the limitations of their devices, while many start-ups have come and gone. A long list of new hopefuls believe they have the solution physicians have desired. Now all they have to do is convince the physicians, who, when it comes to vascular closure devices, are slow to recognize clinical data but quick to embrace a device that feels right to them.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel